Mitogen-activated protein kinase 14:Mitogen-activated protein kinase-activated protein kinase 2 complex (p38α:MK2 complex)

The p38α:MK2 complex is a pivotal signaling unit within the mitogen-activated protein kinase (MAPK) pathway, formed by the association of the kinase p38α (Mitogen-activated protein kinase 14) and its downstream effector MK2 (Mitogen-activated protein kinase-activated protein kinase 2) [8, 16]. This complex serves as a master regulator of the inflammatory response by controlling the post-transcriptional stability and translation of mRNAs for key proinflammatory cytokines, including TNF-α, IL-1β, and IL-6 [2, 12, 14]. In resting cells, the two proteins form a stable heterodimer in the nucleus; upon stimulation by stress or cytokines, p38α phosphorylates MK2, triggering a conformational change that exposes a nuclear export signal and leads to the translocation of the active complex to the cytoplasm [14, 18]. Therapeutic interest in this complex has surged as a strategy to overcome the limitations of global p38 inhibitors, which failed in clinical trials due to systemic toxicities and a lack of sustained efficacy (tachyphylaxis) [10, 14, 15]. By specifically targeting the p38α:MK2 interface or the complex-bound state, researchers aim to selectively block proinflammatory signaling while preserving the homeostatic and anti-inflammatory functions of other p38α substrates, offering a promising approach for treating rheumatoid arthritis, Alzheimer's disease, and other chronic inflammatory disorders [1, 3, 4, 10].

Other names

p38α:MK2 complexp38 alpha:MAPKAPK2 complexMAPK14:MAPKAPK2 complexp38:MK2 signaling axisp38 MAPK:MK2 complex

Selective inhibition of the p38α-MK2 protein-protein interaction (PPI) or complex-specific kinase inhibition, which prevents the activation of MK2 and subsequent stabilization of proinflammatory cytokine mRNAs (TNF-α, IL-1β, IL-6) while sparing other p38α substrates [1, 2, 12].